Bearing Point Capital LLC Makes New $1.92 Million Investment in Eli Lilly and Company (NYSE:LLY)

Bearing Point Capital LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, Holdings Channel reports. The institutional investor bought 2,486 shares of the company’s stock, valued at approximately $1,919,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Highline Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company’s stock worth $35,000 after buying an additional 20 shares during the last quarter. FPC Investment Advisory Inc. increased its stake in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after acquiring an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. purchased a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $48,000. Compass Financial Services Inc bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $50,000. Finally, Fiduciary Advisors Inc. purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $58,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LLY. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and lowered their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a report on Friday, January 17th. Guggenheim reissued a “buy” rating on shares of Eli Lilly and Company in a research note on Thursday. Finally, Truist Financial upped their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,002.80.

Eli Lilly and Company Trading Up 3.9 %

Shares of NYSE:LLY opened at $825.10 on Friday. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The business’s fifty day simple moving average is $825.36 and its 200-day simple moving average is $815.67. The company has a market capitalization of $782.34 billion, a PE ratio of 70.46, a P/E/G ratio of 1.40 and a beta of 0.51. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter last year, the firm earned $2.58 EPS. The company’s revenue was up 45.2% compared to the same quarter last year. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.